Avandia, Actos get'black box' warning

As of this week, it's become clear critics and activists have won their point. The FDA has announced Avandia and Actos will soon bear a "black-box" warning detailing possible cardiac failure risks faced by some patients. The warnings will also be placed on drugs which combine the drugs with another related medication, such as Avandamet, which includes both Avandia and Metformin.

The FDA has also recently released a review of reports of side effects from taking Avandia and Actos. The studies for significant weight gain and build of fluids, which can be warning signs for heart failure.

To learn more about the new warnings:
- read this Associated Press article (reg. req.)

ALSO:  What will the pharmas do with their army of Avandia salespersons now that demand has dropped? Article

Related Articles:

FDA panel votes to keep Avandia on the market. Report
Avandia risks exposed under deal to post data. Report
Avandia controversy sparks FDA criticism. Report
Glaxo: Avandia critic should pay for stock drop. Report
Diabetes expert issued harsh Avandia critique in 2000. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.